| UHC Commercial Medical & Drug | Benlysta® (Belimumab) – Commercial Medical Benefit Drug Policy | 2025-12-01 |
| UHC Commercial Medical & Drug | Evenity® (Romosozumab-Aqqg) – Commercial Medical Benefit Drug Policy | 2025-12-01 |
| UHC Commercial Medical & Drug | Ophthalmologic Complement Inhibitors – Commercial Medical Benefit Drug Policy | 2025-12-01 |
| UHC Commercial Medical & Drug | Preventive Vaccines (Immunizations) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2025-12-01 |
| UHC Commercial Medical & Drug | Rebyota® (Fecal Microbiota, Live-Jslm) – Commercial Medical Benefit Drug Policy | 2025-12-01 |
| UHC Commercial Medical & Drug | Review at Launch for New to Market Medications – Commercial Medical Benefit Drug Policy | 2025-12-01 |
| UHC Commercial Medical & Drug | Zolgensma® (Onasemnogene Abeparvovec-Xioi) – Commercial Medical Benefit Drug Policy | 2025-12-01 |
| Ambetter Health Alabama Clinical | Concert Genetic Testing: Hematology (V2.2025) | 2025-12-01 |
| Ambetter Health Alabama Clinical | Concert Genetic Testing: Otolaryngology (V2.2025) | 2025-12-01 |
| Ambetter Health Georgia Clinical | Concert Genetic Testing: Hematology | 2025-12-01 |